ENDRA Life Sciences Discounted Cash Flow

ENDRA Life Sciences (NDRA) currently reports a DCF fair value of $0.34. Use the charts on this page to explore ENDRA Life Sciences's DCF fair value history and peer comparisons.

ENDRA Life Sciences's discounted cash flow (DCF) fair value estimate is $0.34, about 94.3% overvalued versus the current market price. DCF models project future free cash flows and discount them back to today — so the result depends on growth, margin, and discount-rate assumptions. Use it as one valuation lens alongside multiples and peer checks on Stockcircle.

Start with the current DCF fair value of $0.34, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for ENDRA Life Sciences, and consider following NDRA for alerts when major investors trade the stock.

ENDRA Life Sciences is classified in the Technology sector. On DCF fair value, it currently shows $0.34. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Technology are usually more informative than comparing NDRA with unrelated industries.